NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
14 March 2025
| Name: | BIOXYNE LIMITED (BXN) | |||||||||
| ISIN: | AU000000BXN6 | |||||||||
| Date of Listing: | 14 December 2000 | |||||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 084 464 193ABN: 97 084 464 193
Registration Date: 23 September 1998
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| BIOXYNE LIMITED | 10/04/2012 | |
| PROBIOMICS LIMITED | 02/05/2005 | 10/04/2012 |
| VRI BIOMEDICAL LIMITED | 02/05/2005 |
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Bioxyne Limited will be lifted immediately following the release by BXN of a clarification announcement to supplement the information required in relation to BXN's announcement "˜BXN Manufactures First Pharmaceuticals Cannabis Gummies' on 21 August 2024. | 18/09/2024 |
The company has signed a 2-year supply agreement with Montu group Pty Ltd for medicinal cannabis pastilles. The agreement has a fixed price for 24 months and a revenue estimate of $28 million. The company received a deposit of over $900,000 and may terminate the agreement if the customer fails to meet the terms. | 18/09/2024 |
On 12 September 2024, ASX required Bioxyne Limited to provide specified information for release to the market in relation to "˜a 2"year manufacture and supply agreement' as announced in BXN's announcement "˜BXN Manufactures First Pharmaceutical Cannabis Gummies' on 21 August 2024. BXN has failed to comply with that requirement. As a consequence, BXN's securities will be suspended from quotation immediately under Listing Rule 17.3.1, until such time as ASX is satisfied with BXN's compliance with the Listing Rules and that it is otherwise appropriate for BXN's securities to be reinstated to quotation. | 13/09/2024 |
The suspension of trading in the securities of Bioxyne Limited will be lifted immediately following release of an announcement by BXN confirming that it will not proceed with a proposed acquisition. | 04/11/2021 |
The Company advises that it has determined not to proceed with the proposed acquisition at this time. | 04/11/2021 |
The company releases a letter to its shareholders regarding its AGM. | 29/10/2021 |
The company's AGM will be held virtually at 11.30am AEDT on Tuesday 30 November 2021. | 29/10/2021 |
The securities of Bioxyne Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BXN, pending the release of an announcement regarding a potential acquisition. | 29/10/2021 |
The suspension of trading in the securities of Bioxyne Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the completion of an underwritten share placement. Security Code: BXN | 20/02/2013 |
The securities of Bioxyne Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of an underwritten share placement to assist with transaction costs following the entry into a conditional non-binding proposal to acquire Vitality Devices Pty Limited. Security Code: BXN | 20/02/2013 |
The suspension of trading in the securities of Bioxyne Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the results and data from its independent clinical research organisation. | 28/06/2012 |
company advises that its Fully Paid Ordinary shares will remain in suspension until the results of the clinical trials are fully assessed. The Company has received both the initial results and further very detailed analyses of the data. The analysis is ongoing and now requires professional validation. The Company believes that it will be in a position to release a detailed announcement after this review on Wednesday, 27 June 2012 | 25/06/2012 |
The securities of Bioxyne Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company in relation to the results and data from its independent clinical research organisation which are continuing to be assessed. | 15/06/2012 |
name changed from Probiomics Limited | 10/04/2012 |
The suspension of trading in the securities of Bioxyne Limited will be lifted immediately following the release by BXN of a clarification announcement to supplement the information required in relation to BXN's announcement "˜BXN Manufactures First Pharmaceuticals Cannabis Gummies' on 21 August 2024. | 18/09/2024 |
The company has signed a 2-year supply agreement with Montu group Pty Ltd for medicinal cannabis pastilles. The agreement has a fixed price for 24 months and a revenue estimate of $28 million. The company received a deposit of over $900,000 and may terminate the agreement if the customer fails to meet the terms. | 18/09/2024 |
On 12 September 2024, ASX required Bioxyne Limited to provide specified information for release to the market in relation to "˜a 2"year manufacture and supply agreement' as announced in BXN's announcement "˜BXN Manufactures First Pharmaceutical Cannabis Gummies' on 21 August 2024. BXN has failed to comply with that requirement. As a consequence, BXN's securities will be suspended from quotation immediately under Listing Rule 17.3.1, until such time as ASX is satisfied with BXN's compliance with the Listing Rules and that it is otherwise appropriate for BXN's securities to be reinstated to quotation. | 13/09/2024 |
The suspension of trading in the securities of Bioxyne Limited will be lifted immediately following release of an announcement by BXN confirming that it will not proceed with a proposed acquisition. | 04/11/2021 |
The Company advises that it has determined not to proceed with the proposed acquisition at this time. | 04/11/2021 |
The company releases a letter to its shareholders regarding its AGM. | 29/10/2021 |
The company's AGM will be held virtually at 11.30am AEDT on Tuesday 30 November 2021. | 29/10/2021 |
The securities of Bioxyne Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BXN, pending the release of an announcement regarding a potential acquisition. | 29/10/2021 |
The suspension of trading in the securities of Bioxyne Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the completion of an underwritten share placement. Security Code: BXN | 20/02/2013 |
The securities of Bioxyne Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of an underwritten share placement to assist with transaction costs following the entry into a conditional non-binding proposal to acquire Vitality Devices Pty Limited. Security Code: BXN | 20/02/2013 |
The suspension of trading in the securities of Bioxyne Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the results and data from its independent clinical research organisation. | 28/06/2012 |
company advises that its Fully Paid Ordinary shares will remain in suspension until the results of the clinical trials are fully assessed. The Company has received both the initial results and further very detailed analyses of the data. The analysis is ongoing and now requires professional validation. The Company believes that it will be in a position to release a detailed announcement after this review on Wednesday, 27 June 2012 | 25/06/2012 |
The securities of Bioxyne Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company in relation to the results and data from its independent clinical research organisation which are continuing to be assessed. | 15/06/2012 |
name changed from Probiomics Limited | 10/04/2012 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 13/10/2023 | Samuel Watson | 20,999,362 | $0.013 | $264,000 |
| 06/10/2023 | Anthony Ho | 712,817 | $0.012 | $8,554 |
| 21/03/2022 | Anthony Ho | 287,183 | $0.020 | $5,600 |
| 07/10/2019 | Anthony Ho | 525,000 | $0.021 | $11,025 |
| 31/05/2019 | Anthony Ho | 800,000 | $0.017 | $13,600 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Anthony Ho | Non Exec Chairman | 12/11/2012 |
| Samuel Watson | Managing Director, CEO | 19/05/2023 |
| Jason Hine | Non Exec Director | 21/05/2023 |
| Guy Robertson | Executive Director, CFO, Company Secretary | 01/09/2016 |
| Rachel Qian | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| NH Chua | Director, CEO | 19/04/2017 | 17/11/2023 |
| Peter Hughes-Hallett | Non Exec Director | 01/05/2018 | 21/05/2023 |
| Patrick Ford | Non Exec Director | 20/05/2005 | 30/06/2022 |
| Max Parkin | Director | 13/06/2017 | 17/01/2019 |
| Peter French | Executive Director | 15/02/2016 | 15/02/2018 |
| George Cameron-Dow | Non Exec Director | 21/07/2014 | 18/11/2016 |
| Jarrod White | CFO | 18/02/2013 | 01/09/2016 |
| Jeremy Cook | Non Exec Director | 13/12/2012 | 21/07/2014 |
| Phillip Comans | CEO | 12/12/2012 | 02/12/2013 |
| Ashok Jairath | CFO | 27/07/2007 | 18/02/2013 |
| David Radford | Managing Director | 04/04/2012 | 12/12/2012 |
| Ian Mutton | Chairman | 04/04/2012 | 29/11/2012 |
| William Harrison | Director | 04/04/2012 | 29/11/2012 |
| Glenn Crisp | Non Exec Director | 04/04/2012 | 30/10/2012 |
| Douglas Wilson | Director | 17/04/2012 | 26/10/2012 |
| Simon O'Loughlin | Non Exec Director | 31/07/2008 | 04/04/2012 |
| Simon Taylor | Non Exec Director | 25/07/2008 | 04/04/2012 |
| Bradley Walsh | Non Exec Director | 23/06/2008 | 07/08/2008 |
| Ronald Penny | Non Exec Director | 18/02/2005 | 06/08/2008 |
| Bryan Gardiner | Non Exec Chairman | 18/02/2005 | 23/06/2008 |
| Kim Slatyer | CEO | 23/09/1998 | 11/03/2008 |
| Victor Garland | Non Exec Chairman | 18/02/2005 | 20/05/2005 |
| Geoffrey Wild | Non Exec Director | 07/11/2003 | 18/05/2005 |
| Sally Capp | Non Exec Director | 29/05/2003 | 26/11/2004 |
| James Grant | Chairman | 29/05/2003 | 04/07/2004 |
| Ronald Rowland | Non Exec Director | 29/05/2003 | 30/06/2004 |
| Glyn Tonge | Non Exec Director | 10/09/2001 | 27/11/2003 |
| Ronald Deane | Chairman | 24/04/2003 | 03/11/2003 |
| Jack Cade | Non Exec Director | 01/11/2000 | 03/11/2003 |
| Kenneth Baxter | Non Exec Director | 01/11/2000 | 29/05/2003 |
| Leon Ivory | Executive Director | 23/09/1998 | 29/05/2003 |
| Robert Clancy | Non Exec Director | 29/05/2001 | 18/07/2002 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
